Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders

Rhea-AI Summary

Provectus Biopharmaceuticals (OTCQB: PVCT) has announced its 2025 annual stockholder meeting will be held on June 18, 2025, at 4:00 p.m. Eastern Time at the Hilton Knoxville in Tennessee. The company will make the Annual Meeting accessible via Zoom Webinar, allowing shareholders to participate remotely. Stockholders can access the meeting materials, including the Proxy Statement, Notice of Internet Availability, and 2024 Annual Report, through the company's website. The virtual attendance option provides increased accessibility for shareholders to participate in the meeting activities and receive company updates.

KNOXVILLE, Tenn., June 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2025 annual stockholder meeting (the “Annual Meeting”), including shareholder meeting activities and a company update, will also be accessible by Zoom Webinar. The meeting will be held on Wednesday, June 18, 2025, at the Hilton Knoxville, located at 501 West Church Avenue, Knoxville, Tenn., beginning at 4:00 p.m. Eastern Time.

The webinar of the Annual Meeting may be accessed by registering in advance at:
https://us06web.zoom.us/webinar/register/WN_NHDxe61oQDi-t84JgMylsg#/registration.

Annual Meeting materials, including the Company’s Proxy Statement, Notice of Internet Availability, and 2024 Annual Report, are available on Provectus’s website at https://www.provectusbio.com/annual-meeting/.

About Provectus

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecules called halogenated xanthenes. Provectus’s lead molecule is named Rose Bengal Sodium.

Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.

Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at www.provectusbio.com.

Forward Looking Statements

The information in this press release may include “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of:

• The Company’s Annual Report on Form 10-K for the period ended December 31, 2024, and
• Provectus’s Quarterly Report on Form 10-Q for the period ended March 31, 2025.

Contacts:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
(866) 594-5999

Investor Relations & Media
Susan Xu
sxu@allianceadvisors.com
(778) 323-0959

FAQ

When is Provectus Biopharmaceuticals (PVCT) 2025 annual stockholder meeting?

The annual stockholder meeting will be held on Wednesday, June 18, 2025, at 4:00 p.m. Eastern Time at the Hilton Knoxville, Tennessee.

How can shareholders attend the PVCT 2025 annual meeting virtually?

Shareholders can attend virtually by registering for the Zoom Webinar through the provided registration link on the company's website.

Where can investors find Provectus Biopharmaceuticals' 2025 annual meeting materials?

Annual Meeting materials, including the Proxy Statement, Notice of Internet Availability, and 2024 Annual Report, are available on Provectus's website at provectusbio.com/annual-meeting.

What is the location of PVCT's 2025 annual stockholder meeting?

The meeting will be held at the Hilton Knoxville, located at 501 West Church Avenue, Knoxville, Tennessee.